Company: IMNN
Filing Date: 2025-07-14
Form Type: 8-K
Source: 0001641172-25-019541
Chunk: 0

Company: Imunon, Inc.
Filing Date: 2025-07-14
Form: 8-K
Item: Item 3.01
Chunk 0
---
Item 3.01      Notice of Delisting or Failure to Satisfy a Continued  

Delisting
Notice

As
previously disclosed, on November 26, 2024, Imunon, Inc. (“the Company”) received a letter from the staff (the “ Staff”)
of The Nasdaq Stock Market LLC (“ Nasdaq”) indicating that, based upon the closing bid price of the Company’s common
stock, for the previous 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid
price of $1.00 per share (the “ Minimum Bid Price Requirement”) for continued listing on The Nasdaq Capital Market, as set
forth in Nasdaq Listing Rule 5550(a)(2) (the “ Original Notice”). As the Company did not regain compliance with the Minimum
Bid Price Requirement by May 27, 2025, and it was determined that the Company is not eligible for another 180 calendar-day extension
because it did not meet the minimum stockholders’ equity initial listing requirements of $5,000,000 for The Nasdaq Capital Market,
as set forth under Nasdaq Listing Rule 5505(b), the Company received a delisting determination letter on May 28, 2025 (the “ Delisting
Determination Letter”).

As
previously reported, the Company received a deficiency letter on May 19, 2025 from the Staff notifying the Company that it is no longer
in compliance with the minimum stockholders’ equity requirement (the “ Minimum Stockholders’ Equity Requirement”)
for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(1). Pursuant to Nasdaq Listing Rule 5810(d)(2),
the failure to comply with the Minimum Stockholders’ Equity Requirement has individually become an additional and separate basis
for delisting.

The
Delisting Determination Letter stated that unless the Company requested a hearing before a Nasdaq Hearing Panel (“ Panel”)
to appeal Nasdaq’s delisting determination by June 4, 2025, trading of the common stock will be suspended at the opening of business
on June 6, 2025, and the Company’s common stock will be delisted from Nasdaq. The Company timely requested a hearing before the
Panel, which request stayed any further suspension or delisting action by Nasdaq, pending the ultimate conclusion of the hearing process.

On
July 11, 2025, the Panel notified the Company